Product

Details:​

A synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH) modified with a trans-3-hexenoic acid group to extend its stability and half-life. It acts selectively on the pituitary gland to stimulate the physiological, pulsatile release of endogenous growth hormone (GH) and subsequent downstream IGF-1, avoiding the supraphysiological spikes, receptor downregulation, and negative feedback suppression common with exogenous GH administration.

​

Key Benefits:

• Selective Visceral Adipose Tissue (VAT) Reduction: Uniquely effective at mobilizing and burning deep, inflammatory visceral fat (abdominal and organ fat) rather than just subcutaneous fat.

• Preservation of Endogenous Pituitary Dynamics: Stimulates natural, rhythmic GH pulses that preserve the body's native somatostatin-regulated feedback loop without shutting down natural hormone production.

• Neutral Glycemic Profile: Unlike exogenous human growth hormone, it shows minimal disruption to fasting blood glucose and insulin sensitivity when dosed within therapeutic protocols.

• Cardiometabolic & Lipid Optimization: Clinical research demonstrates meaningful reductions in circulating triglycerides, non-HDL cholesterol, and carotid intima-media thickness.

• Neuroprotective & Cognitive Support: Emerging research links improved endogenous GHRH/GH signaling via Tesamorelin to enhanced executive function, memory processing, and reduced neuroinflammation.

​

Ideal For:

• Targeted visceral fat loss and body recomposition, particularly for stubborn intra-abdominal adiposity and metabolic central obesity.

• Anti-aging and vitality protocols seeking the systemic benefits of elevated GH/IGF-1 (skin elasticity, joint support, lean mass preservation) without suppressing native endocrine function.

• Cardiometabolic risk reduction, especially for individuals addressing elevated triglycerides and chronic metabolic inflammation.